Literature DB >> 28165640

Significant disparities in allergy prevalence and microbiota between the young people in Finnish and Russian Karelia.

L Ruokolainen1, L Paalanen2, A Karkman1, T Laatikainen2,3, L von Hertzen4, T Vlasoff5, O Markelova6, V Masyuk7, P Auvinen8, L Paulin8, H Alenius9,10, N Fyhrquist9, I Hanski1, M J Mäkelä4, E Zilber11, P Jousilahti2, E Vartiainen2, T Haahtela4.   

Abstract

BACKGROUND: Atopic allergy has been more common among schoolchildren in Finland, as compared to Russian Karelia. These adjacent regions show one of the most contrasting socio-economical differences in the world.
OBJECTIVE: We explored changes in allergy from school age to young adulthood from 2003 to 2010/2012 in these two areas. The skin and nasal microbiota were also compared.
METHODS: Randomly selected children from Finnish (n = 98) and Russian Karelia (n = 82) were examined in 2003, when the children were 7-11 years of age, and again in 2010 (Finnish Karelia) and 2012 (Russian Karelia). We analysed self-reported allergy symptoms and sensitization to common allergens by serum sIgE values. The skin (volar forearm) and nasal mucosa microbiota, collected in 2012 (aged 15-20 years), identified from DNA samples, were compared with multivariate methods.
RESULTS: Asthma, hay fever, atopic eczema, self-reported rhinitis, as well as atopic sensitization, were threefold to 10-fold more common in Finland, as compared to Russian Karelia. Hay fever and peanut sensitization were almost non-existent in Russia. These patterns remained throughout the 10-year follow-up. Skin microbiota, as well as bacterial and fungal communities in nasal mucosa, was contrastingly different between the populations, best characterized by the diversity and abundance of genus Acinetobacter; more abundant and diverse in Russia. Overall, diversity was significantly higher among Russian subjects (Pskin < 0.0001, Pnasal-bacteria < 0.0001 and Pnasal-fungi < 0.01). Allergic diseases were not associated with microbial diversity in Finnish subjects. CONCLUSIONS AND CLINICAL RELEVANCE: Differences in allergic phenotype, developed in early life, remain between populations. A parallel difference in the composition of skin and nasal microbiota suggests a potential underlying mechanism. Our results also suggest that high abundance and diversity of Acinetobacter might contribute to the low allergy prevalence in Russia. Implications of early-life exposure to Acinetobacter should be further investigated.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Finland; Russia; allergy; microbiota; specific IgE

Mesh:

Year:  2017        PMID: 28165640     DOI: 10.1111/cea.12895

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  28 in total

Review 1.  Environmental exposures and mechanisms in allergy and asthma development.

Authors:  Liza Bronner Murrison; Eric B Brandt; Jocelyn Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

2.  Epigenetic Differences in Long Non-coding RNA Expression in Finnish and Russian Karelia Teenagers With Contrasting Risk of Allergy and Asthma.

Authors:  Joseph Ndika; Piia Karisola; Vilma Lahti; Nanna Fyhrquist; Tiina Laatikainen; Tari Haahtela; Harri Alenius
Journal:  Front Allergy       Date:  2022-04-27

Review 3.  Early life microbial exposures and allergy risks: opportunities for prevention.

Authors:  Harald Renz; Chrysanthi Skevaki
Journal:  Nat Rev Immunol       Date:  2020-09-11       Impact factor: 53.106

Review 4.  Human Milk and Allergic Diseases: An Unsolved Puzzle.

Authors:  Daniel Munblit; Diego G Peroni; Alba Boix-Amorós; Peter S Hsu; Belinda Van't Land; Melvin C L Gay; Anastasia Kolotilina; Chrysanthi Skevaki; Robert J Boyle; Maria Carmen Collado; Johan Garssen; Donna T Geddes; Ralph Nanan; Carolyn Slupsky; Ganesa Wegienka; Anita L Kozyrskyj; John O Warner
Journal:  Nutrients       Date:  2017-08-17       Impact factor: 5.717

5.  Skin microbiota and allergic symptoms associate with exposure to environmental microbes.

Authors:  Jenni Lehtimäki; Hanna Sinkko; Anna Hielm-Björkman; Elina Salmela; Katriina Tiira; Tiina Laatikainen; Sanna Mäkeläinen; Maria Kaukonen; Liisa Uusitalo; Ilkka Hanski; Hannes Lohi; Lasse Ruokolainen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

6.  The need for European OneHealth/EcoHealth networks.

Authors:  Hans Keune; Lucette Flandroy; Séverine Thys; Nick De Regge; Marcella Mori; Nicolas Antoine-Moussiaux; Maarten P M Vanhove; Javiera Rebolledo; Steven Van Gucht; Isra Deblauwe; Wim Hiemstra; Barbara Häsler; Aurélie Binot; Sara Savic; Simon R Ruegg; Sjerp De Vries; Julie Garnier; Thierry van den Berg
Journal:  Arch Public Health       Date:  2017-10-26

7.  Allergen-specific IgE and IgG4 patterns among patients with different allergic diseases.

Authors:  Olga Smoldovskaya; Guzel Feyzkhanova; Sergei Voloshin; Alla Arefieva; Antonina Chubarova; Ludmila Pavlushkina; Tatiana Filatova; Eugenia Antonova; Elena Timofeeva; Veronika Butvilovskaya; Yuri Lysov; Alexander Zasedatelev; Alla Rubina
Journal:  World Allergy Organ J       Date:  2018-12-03       Impact factor: 4.084

Review 8.  The Role of the Environment and Exposome in Atopic Dermatitis.

Authors:  Nicholas Stefanovic; Alan D Irvine; Carsten Flohr
Journal:  Curr Treat Options Allergy       Date:  2021-05-21

Review 9.  The skin microbiome: impact of modern environments on skin ecology, barrier integrity, and systemic immune programming.

Authors:  Susan L Prescott; Danica-Lea Larcombe; Alan C Logan; Christina West; Wesley Burks; Luis Caraballo; Michael Levin; Eddie Van Etten; Pierre Horwitz; Anita Kozyrskyj; Dianne E Campbell
Journal:  World Allergy Organ J       Date:  2017-08-22       Impact factor: 4.084

Review 10.  The Prebiotic and Probiotic Properties of Human Milk: Implications for Infant Immune Development and Pediatric Asthma.

Authors:  Shirin Moossavi; Kozeta Miliku; Shadi Sepehri; Ehsan Khafipour; Meghan B Azad
Journal:  Front Pediatr       Date:  2018-07-24       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.